IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 2013;6(11):2535-2541

Original Article
Loss of RhoGDI is a novel independent prognostic factor in hepatocellular carcinoma

Weidong Li, Hui Wang, Xuejun Jin, Liang Zhao

Department of Medical Oncology, Affiliated Tumor Hospital of Guangzhou Medical University, Guangzhou, China; Department of Pathology,
Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Pathology, School of Basic Medical Sciences, Southern
Medical University, Guangzhou, China. Equal contributors.

Received September 5, 2013; Accepted October 12, 2013; Epub October 15, 2013; Published November 1, 2013

Abstract: RhoGDI (Rho GDP-dissociation inhibitor alpha or RhoGDIα) has been identified as a regulator of Rho GTPases, which are essential
for tumor progression, but its role in cancer remains controversial and little is known in hepatocellular carcinoma (HCC). Using
immunohistochemistry, we analyzed RhoGDI expression in 147 clinicopathologically characterized HCC cases. RhoGDI expression was
detected in cytoplasm of HCC tissues. Statistical analysis showed that there was no relationship between RhoGDI expression and
clinicopathological features. Importantly, a significant trend was identified between loss of RhoGDI expression in HCC and worsening clinical
prognosis. Multivariate survival analysis showed that negative RhoGDI expression was recognized as an independent prognostic factor of
patient’s survival. Our results suggest that RhoGDI protein is a valuable marker of prognosis for patients with HCC. (IJCEP1309016).

Keywords: Rho GDP-dissociation inhibitor alpha, hepatocellular carcinoma, poor prognosis

Address correspondence to: Liang Zhao, Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Tel: 86-
20-62787274; Fax: 86-20-62787274; E-mail: liangsmu@gmail.com